NDA 219008 · Janssen Biotech
Lazcluze
Lazertinib Mesylate · Oral · Kinase Inhibitor
NovelPriority reviewCDER novel approval, Aug 19, 2024: To treat non-small cell lung cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 19, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
40
4 Phase 3, 9 recruiting
FAERS reports
865
621 serious, 35 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 5, 2026.
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 )
Mechanism: Lazertinib is a kinase inhibitor of epidermal growth factor receptor (EGFR) that inhibits EGFR exon 19 deletions and exon 21 L858R substitution mutations at lower concentrations than wild-type EGFR. In human NSCLC cells and mouse xenograft models of EGFR exon 19 deletions or EGFR L858R substitution mutations, lazertinib demonstrated anti-tumor activity. Treatment with lazertinib in combination with amivantamab increased in vivo anti-tumor activity compared to either agent alone in a mouse xenograft model of human NSCLC with an EGFR L858R mutation.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 14, 2025 Supplement 2 · Efficacy Letter
- Aug 19, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
- LAZCLUZE · LAZERTINIB MESYLATE EQ 80MG BASE · TABLET, ORAL · Prescription
- LAZCLUZE · LAZERTINIB MESYLATE EQ 240MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lazertinib" as an intervention, any sponsor and status, largest first.
- A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral NeuropathyPivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT07774520 · 1,173 participants (planned) · Start May 26, 2026 · Primary completion Jun 1, 2029
Drug: Supplementation of magnesium lactate; Dose reduction of lezertinib · For: Non-small Cell Lung Cancer(NSCLC); EGFR Mutant
Sites: Seoul, South Korea
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04487080 · 1,074 participants · Start Sep 30, 2020 · Primary completion Aug 11, 2023
Drug: Amivantamab; Osimertinib and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Goodyear, Arizona; Yuma, Arizona; Long Beach, California · 269 sites in all
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailurePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04988295 · 776 participants · Start Nov 17, 2021 · Primary completion Jul 10, 2023
Drug: Lazertinib; Amivantamab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Mobile, Alabama; Tucson, Arizona; Duarte, California · 249 sites in all
- Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02609776 · 751 participants · Start May 24, 2016 · Primary completion Dec 31, 2026
Drug: Amivantamab; Amivantamab and 3 more · For: Non-Small-Cell Lung Cancer
Sites: Duarte, California; La Jolla, California; Orange, California · 69 sites in all
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04077463 · 701 participants · Start Sep 4, 2019 · Primary completion Feb 12, 2027
Drug: Lazertinib; Amivantamab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Los Angeles, California; Orange, California; San Francisco, California · 78 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05498428 · 520 participants (planned) · Start Nov 11, 2022 · Primary completion Aug 17, 2027
Drug: Amivantamab; Lazertinib and 4 more · For: Carcinoma, Non-small-Cell Lung
Sites: La Jolla, California; Orange, California; Stanford, California · 110 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06667076 · 480 participants (planned) · Start Dec 16, 2024 · Primary completion May 23, 2029
Drug: Amivantamab; Lazertinib and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Daphne, Alabama; Huntsville, Alabama; Goodyear, Arizona · 205 sites in all
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05388669 · 418 participants · Start Aug 5, 2022 · Primary completion Jan 3, 2024
Drug: Lazertinib; Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) and 1 more · For: Advanced or Metastatic Non-small Cell Lung Cancer
Sites: Duarte, California; Irvine, California; Long Beach, California · 187 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash162
- infusion related reaction96
- paronychia69
- off label use60
- neuropathy peripheral53
- fatigue46
- diarrhoea41
- nausea36
- pruritus35
- stomatitis32
- dermatitis acneiform31
- dyspnoea29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 13 |
| 2022 | 21 |
| 2023 | 12 |
| 2024 | 93 |
| 2025 | 330 |
| 2026 | 396 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lazcluze (Lazertinib Mesylate)
2024 spending
$7.1M
Beneficiaries
183
398 claims
Per beneficiary
$38,932
$541.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $7,124,540 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, et al. · Ann Oncol 2024 · Clinical Trial, Phase III
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Yang JC, Lu S, Hayashi H, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Leighl NB, Akamatsu H, Lim SM, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.
Ma Z, Cao F, Liao M, et al. · BMJ 2025 · Network Meta-Analysis, Systematic Review
- Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
Cho BC, Li W, Spira AI, et al. · J Thorac Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.